RID Inc. develops rapid diagnostic tests using mass spectrometry, significantly reducing microbiology testing times. Their technology enables faster identification of pathogens, leading to quicker and more effective treatment decisions.
Funding
Funding not disclosed
Founders
Product
Problem
Conventional microbiology testing methods for infectious diseases can take days to deliver results, delaying appropriate treatment and potentially worsening patient outcomes. The lengthy turnaround time hinders timely clinical decision-making, increases healthcare costs, and contributes to the overuse of broad-spectrum antibiotics.
Solution
Rapid Infection Diagnostics (RID) Inc. offers a suite of rapid diagnostic tests leveraging advanced mass spectrometry to significantly reduce microbiology testing times. Their technology, centered around the Hopper™ platform, enables identification (ID) and antibiotic susceptibility testing (AST) of microbes in hours instead of days. By providing actionable results faster, RID's solution facilitates quicker and more effective treatment decisions, ultimately improving patient care and reducing the spread of antimicrobial resistance. The platform's high-throughput capabilities are designed to meet the demands of large microbiology laboratories.
Target Audience
RID's primary customers are large microbiology laboratories seeking to improve the speed and efficiency of their infectious disease diagnostics.
Features
- Hopper™ platform: A rapid, high-throughput metabolomics-based system for microbial ID and AST.
- Mass spectrometry-based technology: Provides accurate and comprehensive analysis of microbial samples.
- Rapid turnaround time: Reduces testing times from days to hours, enabling faster clinical intervention.
- Single-platform solution: Integrates ID and AST workflows for streamlined testing.
- One-button solution: Simplifies microbiology testing.